Efficacy of Dapagliflozin in Diabetes Associated Peripheral Neuropathy
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Diabetic peripheral neuropathy(DPN) is a length dependent axonal neuropathy that affects at
least 50% of patients with diabetes mellitus. DPN is often asymptomatic during the early
stages of diabetes ,however, once symptoms and overt deficits have developed, it cannot be
reversed. Early diagnosis of neuropathy is important because early diagnosis and timely
intervention might prevent the development and progression of diabetic neuropathy.Though
glycemic control has been shown to prevent the progression of diabetic microvascular
complications including diabetic peripheral neuropathy in Type I DM, such strict glycemic
control has not shown to improve diabetic peripheral neuropathy in Type 2 DM. There are only
few animal studies conducted so far which have shown that the use of SGLT2 inhibitors
prevents the progression of diabetic peripheral neuropathy.Thus the investigators postulate
that the use of SGLT2 inhibitor in patients with Type 2 Diabetes Mellitus might be beneficial
in the prevention of progression of diabetic peripheral neuropathy as well as reverse it.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Postgraduate Institute of Medical Education and Research